IGC Pharma, Inc. IGC
i
Market datapartial · fetched 2026-11-12T01:37:17.480Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-02-19
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T01:00:00.07951729Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T01:37:15.835033+00:00
IGC Pharma, Inc. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 1.25 | 459.5% | 58.3% | |||
| 30Δ | 2.07 | 459.1% | 53.8% | |||
| 35Δ | 2.90 | 458.7% | 49.4% | |||
| 40Δ | 3.72 | 458.3% | 44.9% | |||
| 45Δ | 4.55 | 457.8% | 40.5% | |||
| 50Δ | 5.37 | 457.4% | 36.1% | |||
| 55Δ | 6.20 | 457.0% | 31.6% | |||
| 60Δ | 7.02 | 456.6% | 27.2% | |||
| 65Δ | ||||||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.25
- IV
- 459.5%
- B/E move
- 58.3%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.07
- IV
- 459.1%
- B/E move
- 53.8%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.90
- IV
- 458.7%
- B/E move
- 49.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.72
- IV
- 458.3%
- B/E move
- 44.9%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.55
- IV
- 457.8%
- B/E move
- 40.5%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.37
- IV
- 457.4%
- B/E move
- 36.1%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.20
- IV
- 457.0%
- B/E move
- 31.6%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.02
- IV
- 456.6%
- B/E move
- 27.2%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
IMCR
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is…
More →IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology and inflammation in the United…
More →IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapies for oncology and infectious diseases. The company is headquartered in Exton, Pennsylvania.
More →IMRX
Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its proprietary drug…
More →IMTX
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in…
More →IMUX
Description unavailable
More →